InsiderSource
TRVI

Trevi Therapeutics, Inc.

SEC CIK 1563880
$14.21 +24.1% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
32
Most recent
Advertisement

At a glance

Insiders at TRVI have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Simon Farrell sold $517.8K of TRVI, trimming their stake 49%.

Most active filer: Good Jennifer L, with 10 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TRVI, newest first
View on SEC EDGAR ↗
TRVI
Trevi Therapeutics, Inc.
Sell SCIASCIA THOMAS · Chief Scientific Officer · Open-market sale · filed Mar 26, 2025 ΔOwn −1.2%

Sciascia Thomas sold $17.4K of TRVI, trimming their stake 1%.

−$17.4K
2,631 sh @ $7
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed Mar 25, 2025 ΔOwn −2.4%

Good Jennifer L sold $34.6K of TRVI, trimming their stake 2%.

−$34.6K
5,263 sh @ $7
Advertisement
TRVI
Trevi Therapeutics, Inc.
Sell Simon Farrell · Chief Commercial Officer · Open-market sale · filed Mar 12, 2025 ΔOwn −49%

Simon Farrell sold $517.8K of TRVI, trimming their stake 49%.

−$517.8K
76,963 sh @ $7
TRVI
Trevi Therapeutics, Inc.
Sell Simon Farrell · Chief Commercial Officer · Open-market sale · filed Mar 12, 2025 ΔOwn −5.4%

Simon Farrell sold $31.1K of TRVI, trimming their stake 5%.

−$31.1K
4,350 sh @ $7
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed Sep 9, 2024 ΔOwn −0.9%

Good Jennifer L sold $5.6K of TRVI, trimming their stake 1%.

−$5.6K
1,840 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed Sep 9, 2024 ΔOwn −1.9%

Good Jennifer L sold $12.8K of TRVI, trimming their stake 2%.

−$12.8K
4,219 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed Sep 5, 2024 ΔOwn −16%

Good Jennifer L sold $125.3K of TRVI, trimming their stake 16%.

−$125.3K
40,277 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed Sep 5, 2024 ΔOwn −4.9%

Good Jennifer L sold $33.2K of TRVI, trimming their stake 5%.

−$33.2K
10,981 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed Sep 5, 2024 ΔOwn −1.8%

Good Jennifer L sold $11.7K of TRVI, trimming their stake 2%.

−$11.7K
3,863 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell Meeker David P · Director · Open-market sale · filed Aug 29, 2024 ΔOwn −1.3%

Meeker David P sold $13.4K of TRVI, trimming their stake 1%.

−$13.4K
4,555 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell SCIASCIA THOMAS · Chief Scientific Officer · Open-market sale · filed Aug 21, 2024 ΔOwn −7.0%

Sciascia Thomas sold $48.9K of TRVI, trimming their stake 7%.

−$48.9K
16,496 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell SCIASCIA THOMAS · Chief Scientific Officer · Open-market sale · filed Aug 16, 2024 ΔOwn −7.8%

Sciascia Thomas sold $51.4K of TRVI, trimming their stake 8%.

−$51.4K
18,660 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell SCIASCIA THOMAS · Chief Scientific Officer · Open-market sale · filed Aug 16, 2024 ΔOwn −5.5%

Sciascia Thomas sold $35.5K of TRVI, trimming their stake 5%.

−$35.5K
12,745 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell SCIASCIA THOMAS · Chief Scientific Officer · Open-market sale · filed May 31, 2024 ΔOwn −20%

Sciascia Thomas sold $136.1K of TRVI, trimming their stake 20%.

−$136.1K
53,368 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed May 24, 2024 ΔOwn −7.5%

Delfini Lisa sold $11.5K of TRVI, trimming their stake 8%.

−$11.5K
4,350 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed May 22, 2024 ΔOwn −11%

Good Jennifer L sold $71.6K of TRVI, trimming their stake 11%.

−$71.6K
25,037 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell GOOD JENNIFER L · Director, President & CEO · Open-market sale · filed May 14, 2024 ΔOwn −2.1%

Good Jennifer L sold $13.3K of TRVI, trimming their stake 2%.

−$13.3K
4,578 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Oct 12, 2023 ΔOwn −2.1%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 2%.

−$1.6K
785 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Sep 13, 2023 ΔOwn −2.0%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 2%.

−$1.6K
711 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Aug 14, 2023 ΔOwn −2.0%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 2%.

−$1.6K
682 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Jul 12, 2023 ΔOwn −2.2%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 2%.

−$1.6K
687 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Jun 14, 2023 ΔOwn −2.0%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 2%.

−$1.6K
610 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed May 15, 2023 ΔOwn −2.0%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 2%.

−$1.6K
562 sh @ $3
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Apr 12, 2023 ΔOwn −3.1%

Delfini Lisa sold $1.5K of TRVI, trimming their stake 3%.

−$1.5K
840 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Mar 15, 2023 ΔOwn −3.5%

Delfini Lisa sold $1.6K of TRVI, trimming their stake 3%.

−$1.6K
892 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Sell Delfini Lisa · Chief Financial Officer · Open-market sale · filed Feb 15, 2023 ΔOwn −27%

Delfini Lisa sold $20.8K of TRVI, trimming their stake 27%.

−$20.8K
8,474 sh @ $2
TRVI
Trevi Therapeutics, Inc.
Buy Meeker David P · Director, 10% Owner · Open-market purchase · filed May 13, 2019 ΔOwn +3.3%

Meeker David P, TRVI's 10% owner, spent $112.5K of their own money on 11,250 shares at $10, growing their stake 3%.

+$112.5K
11,250 sh @ $10
Advertisement

About TRVI insider activity

This page tracks every recent Form 4 filed for Trevi Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TRVI insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Trevi Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.